비교리스트

 카트 문의
시장보고서
상품코드
1678664

세계의 희소 혈우병 인자 시장 규모, 점유율, 동향 분석 : 인자 결핍증 유형별, 약제 클래스별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Factor Deficiency Type, By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

희소 혈우병 인자 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 희소 혈우병 인자 시장 규모는 2030년까지 4억 9,040만 달러에 달하며, 2025-2030년의 CAGR은 6.4%를 기록할 것으로 예측됩니다.

미국 FDA와 같은 규제기관으로부터 판매 승인을 받은 여러 농축 인자가 시장 성장을 크게 촉진할 것으로 예상됩니다. 또한 환자들의 예방요법 채택이 증가함에 따라 향후 수년간 시장 성장을 가속할 것으로 예상됩니다. 중증 희귀 혈우병 인자 장애 환자는 출혈 에피소드를 피하고 삶의 질을 개선하기 위해 예방적 치료를 권장하고 있으며, COVID-19 팬데믹은 시장 성장에 큰 영향을 미쳤습니다.

팬데믹으로 인해 환자 안전과 감염 예방에 대한 관심이 높아진 결과, 특정 응고인자 치료제를 투여할 때 안전 조치에 대한 인식이 높아지고 중요성이 강조되고 있습니다. 의료진과 환자는 적절한 소독, 손 위생, 개인보호구(PPE) 사용 등 치료 투여시 위생 습관을 준수하는 것에 대해 더 많은 주의를 기울이게 되었습니다. 이러한 환자 안전에 대한 강조는 희귀 혈우병 인자 투여에 장기적으로 도움이 될 수 있습니다. 팬데믹으로 인한 어려움에도 불구하고 희귀 혈우병에 대한 특정 응고인자 치료에 대한 수요는 여전히 높습니다. 희귀 혈우병 환자들은 자신의 질환을 효과적으로 관리하고 치료하기 위해 여전히 이러한 치료법이 필요했습니다.

진단 및 치료율을 높이기 위한 정부의 적극적인 노력과 의무화가 시장 성장을 가속하고 있습니다. 예를 들어 미국 의회는 1983년 희귀의약품법(Orphan Drug Act: ODA)을 제정했으며, 1983-2015년 약 3,647개의 의약품이 희귀의약품으로 지정되었고, 미국 FDA는 554개의 의약품을 승인했습니다. 시장 진출기업은 경쟁이 치열한 시장에서 우위를 점하기 위해 혁신적인 제품 출시, 제휴 등 다양한 노력을 기울이고 있습니다. 예를 들어 2022년 11월 FDA는 유전성 혈액 응고 질환인 혈우병 B에 대한 혁신적인 유전자 치료제의 승인을 발표했습니다. 유전자 기반 치료제인 킴리아는 25세 이하의 B세포 전구 혈우병 환자를 치료하는 데 사용됩니다.

희귀 혈우병 인자 시장 : 분석 개요

  • 인자 VII 결핍증은 2024년 35.1%의 점유율을 차지하며 시장을 독점했습니다. 제 XIII 인자 결핍증은 예측 기간 중 가장 빠른 CAGR 7.1%로 성장할 것으로 예상됩니다.
  • 유전자 재조합 치료는 2024년 50.3%의 점유율을 차지하며 시장을 주도했습니다. 예방적 치료는 예측 기간 중 가장 빠른 CAGR 7.5%를 나타낼 것으로 예상됩니다.
  • 병원 약국은 2024년 59.9%로 가장 큰 점유율을 차지했습니다. 온라인 약국은 예측 기간 중 가장 빠른 CAGR 9.2%로 성장할 것으로 예상됩니다.
  • 북미 희귀 혈우병 인자 시장은 2024년 38.7%의 매출 점유율을 차지하며 세계 시장을 독점했습니다. 아시아태평양 희귀 혈우병 인자 시장은 예측 기간 중 가장 빠른 CAGR 6.1%를 나타낼 것으로 예상됩니다.

목차

제1장 분석 방법·범위

제2장 개요

제3장 희소 혈우병 인자 시장 : 변동 요인·동향·범위

  • 시장 연관 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 비즈니스 환경 분석
    • 업계 분석 : Porter's Five Forces 분석
    • PESTEL 분석

제4장 희소 혈우병 인자 시장 : 인자 결핍증 유형별 비즈니스 분석

  • 시장 점유율 : 인자 결핍증 유형별(2024년·2030년)
  • 인자 결핍증 유형별 대시보드
  • 시장 규모 예측과 동향 분석 : 인자 결핍증 유형별(2018-2030년)
  • 제VII 인자 결핍증
  • 제XI 인자 결핍증(혈우병 C)
  • 제XIII 인자 결핍증
  • 기타

제5장 희소 혈우병 인자 시장 : 약제 클래스별 비즈니스 분석

  • 시장 점유율 : 약제 클래스별(2024년·2030년)
  • 약제 클래스별 대시보드
  • 시장 규모 예측과 동향 분석 : 약제 클래스별(2018-2030년)
  • 재조합 요법
  • 혈장 유래 요법
  • 예방적 치료
  • 기타

제6장 희소 혈우병 인자 시장 : 유통 채널별 비즈니스 분석

  • 시장 점유율 : 유통 채널별(2024년·2030년)
  • 유통 채널별 대시보드
  • 시장 규모 예측과 동향 분석 : 유통 채널별(2018-2030년)
  • 병원 약국
  • 소매 약국
  • 온라인 약국
  • 온라인 약국 시장(2018-2030년)

제7장 희소 혈우병 인자 시장 : 지역별 추정·동향 분석

  • 시장 점유율 분석 : 지역별(2024년·2030년)
  • 시장 대시보드 : 지역별
  • 시장 규모 예측과 동향 분석(2018-2030년)
  • 북미
    • 국가별(2018-2030년)
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 국가별(2018-2030년)
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 노르웨이
    • 덴마크
    • 스웨덴
  • 아시아태평양
    • 국가별(2018-2030년)
    • 일본
    • 중국
    • 인도
    • 한국
    • 호주
    • 태국
  • 라틴아메리카
    • 국가별(2018-2030년)
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 국가별(2018-2030년)
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트

제8장 경쟁 구도

  • 참가자 개요
  • 기업의 시장 현황 분석
  • 기업 분류
  • 전략 지도제작
  • 기업 개요/상장기업
    • Takeda Pharmaceutical Company Limited
    • Biogen
    • Novo Nordisk A/S
    • Bayer AG
    • CSL
    • Pfizer Inc.
    • Sanofi
    • F. Hoffmann-La Roche Ltd
    • Swedish Orphan Biovitrum AB(publ)
    • Octapharma AG
    • Grifols, SA
    • BioMarin
KSA 25.04.07

Rare Hemophilia Factors Market Growth & Trends:

The global rare hemophilia factors market size is expected to reach USD 490.4 million by 2030, registering a CAGR of 6.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Several factor concentrates gaining marketing approvals from regulatory bodies, such as the U.S. FDA, are expected to provide a significant push to the market growth. In addition, the rising adoption of prophylaxis treatment by patients is expected to boost market growth in the coming years. Patients with severe rare hemophilia factor disorders are recommended prophylactic treatment to avoid bleeding episodes and improve quality of life. The COVID-19 pandemic had a significant impact on the market growth.

The pandemic's emphasis on patient safety and infection control measures led to an increased awareness and importance placed on safety measures in the administration of specific clotting factor therapies. Healthcare providers and patients became more conscientious about following hygienic practices during treatment administration, such as proper disinfection, hand hygiene, and the use of personal protective equipment. This increased emphasis on patient safety measures may have long-term benefits for the administration of rare hemophilia factors. Despite the challenges posed by the pandemic, there was still a high demand for specific clotting factor therapies for rare hemophilia. Patients with rare hemophilia types still required these therapies to effectively manage and treat their condition.

Favorable government initiatives and mandates to increase diagnosis and treatment rates are boosting market growth. For instance, the U.S. Congress enacted the Orphan Drug Act (ODA) in 1983. From 1983 to 2015, around 3,647 drugs were designated the status of orphan drugs, and 554 drugs were approved by the U.S. FDA. The market players are constantly undertaking initiatives, such as innovative product launches and collaborations, to gain an advantage in the highly competitive market. For instance, in November 2022, the FDA announced its approval of an innovative gene therapy for the treatment of genetic blood-clotting Hemophilia B disorder. Kymriah, the gene-based therapy, is used for the treatment of B-cell precursor hemophilia patients below 25 years of age.

Rare Hemophilia Factors Market Report Highlights:

  • Factor VII deficiency dominated the market and accounted for a share of 35.1% in 2024. Factor XIII deficiency is expected to grow at the fastest CAGR of 7.1% over the forecast period.
  • Recombinant therapies led the market and accounted for a share of 50.3% in 2024. Prophylactic treatments are expected to register the fastest CAGR of 7.5% over the forecast period.
  • Hospital pharmacies held the largest market share of 59.9% in 2024. Online pharmacies are projected to grow at the fastest CAGR of 9.2% over the forecast period.
  • North America rare hemophilia factors market dominated the global market with a revenue share of 38.7% in 2024. Asia Pacific rare hemophilia factors market is expected to register the fastest CAGR of 6.1% in the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Factor Deficiency Type
    • 1.2.2. Drug Class
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Rare Hemophilia Factors Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Rare Hemophilia Factors Market: Factor Deficiency Type Business Analysis

  • 4.1. Factor Deficiency Type Market Share, 2024 & 2030
  • 4.2. Factor Deficiency Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Factor Deficiency Type, 2018 to 2030 (USD Million)
  • 4.4. Factor VII Deficiency
    • 4.4.1. Factor VII Deficiency Market, 2018 - 2030 (USD Million)
  • 4.5. Factor XI Deficiency (Hemophilia C)
    • 4.5.1. Factor XI Deficiency (Hemophilia C) Market, 2018 - 2030 (USD Million)
  • 4.6. Factor XIII Deficiency
    • 4.6.1. Factor XIII Deficiency Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Rare Hemophilia Factors Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2030
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 5.4. Recombinant Therapies
    • 5.4.1. Recombinant Therapies Market, 2018 - 2030 (USD Million)
  • 5.5. Plasma-derived Therapies
    • 5.5.1. Plasma-derived Therapies Market, 2018 - 2030 (USD Million)
  • 5.6. Prophylactic Treatments
    • 5.6.1. Prophylactic Treatments Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Rare Hemophilia Factors Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
  • 6.7. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Rare Hemophilia Factors Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Takeda Pharmaceutical Company Limited
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Biogen
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Novo Nordisk A/S
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Bayer AG
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. CSL
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Pfizer Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Sanofi
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. F. Hoffmann-La Roche Ltd
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Swedish Orphan Biovitrum AB (publ)
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Octapharma AG
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Grifols, S.A.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. BioMarin
      • 8.5.12.1. Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제